MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? S
- PDF / 1,016,873 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 31 Downloads / 171 Views
MAGNETIC RESONANCE
MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218) Simone Giovanni Gugliandolo 1 & Matteo Pepa 1 & Lars Johannes Isaksson 1,2 & Giulia Marvaso 1,3 & Sara Raimondi 4 & Francesca Botta 5 & Sara Gandini 4 & Delia Ciardo 1 & Stefania Volpe 1,3 & Giulia Riva 1,6 & Damari Patricia Rojas 1 & Dario Zerini 1 & Paola Pricolo 7 & Sarah Alessi 7 & Giuseppe Petralia 3,7 & Paul Eugene Summers 7 & Frnacesco Alessandro Mistretta 8,9 & Stefano Luzzago 8 & Federica Cattani 5 & Ottavio De Cobelli 3,8 & Enrico Cassano 10 & Marta Cremonesi 11 & Massimo Bellomi 3,7 & Roberto Orecchia 12 & Barbara Alicja Jereczek-Fossa 1,3 Received: 16 January 2020 / Revised: 18 June 2020 / Accepted: 23 July 2020 # European Society of Radiology 2020
Abstract Objectives Radiomic involves testing the associations of a large number of quantitative imaging features with clinical characteristics. Our aim was to extract a radiomic signature from axial T2-weighted (T2-W) magnetic resonance imaging (MRI) of the whole prostate able to predict oncological and radiological scores in prostate cancer (PCa). Methods This study included 65 patients with localized PCa treated with radiotherapy (RT) between 2014 and 2018. For each patient, the T2-W MRI images were normalized with the histogram intensity scale standardization method. Features were extracted with the IBEX software. The association of each radiomic feature with risk class, T-stage, Gleason score (GS), extracapsular extension (ECE) score, and Prostate Imaging Reporting and Data System (PI-RADS v2) score was assessed by univariate and multivariate analysis.
Simone Giovanni Gugliandolo and Matteo Pepa contributed equally to this work. The first affiliation was the affiliation at the time of data collection for authors Simone Giovanni Gugliandolo, Delia Ciardo and Giulia Riva. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00330-020-07105-z) contains supplementary material, which is available to authorized users. * Giulia Marvaso [email protected]
6
Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy
7
Division of Radiology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy
1
Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy
8
2
European School of Molecular Medicine, IFOM-IEO Campus, Via Adamello, 16, 20139 Milan, Italy
Division of Urology, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy
9
3
University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy
Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy
10
Breast Imaging Division, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy
11
Radiation Research Unit, IEO, Europ
Data Loading...
